These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 28901856)

  • 21. [What's new in ocular surface disease?].
    Messmer EM; Benitez-Del-Castillo JM; Lambiase A; Doan S
    Ophthalmologe; 2005 Mar; 102(3):293-300. PubMed ID: 15616816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allergic inflammation of the anterior surface of the eye.
    Bielory L
    Allergy Asthma Proc; 2020 Nov; 41(6):449-453. PubMed ID: 33109311
    [No Abstract]   [Full Text] [Related]  

  • 23. Emerging therapies targeting eosinophil-mediated inflammation in chronic allergic conjunctivitis.
    Fernandez A; Asbell P; Roy N
    Ocul Surf; 2022 Oct; 26():191-196. PubMed ID: 35970432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Use of cyclosporine 0.05% in various ocular surface disorders].
    Maĭchuk DIu; Vasil'eva OA; Shokirova MM
    Vestn Oftalmol; 2014; 130(2):68-71. PubMed ID: 24864503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New ocular therapeutics: a view from the patenting perspective.
    Mucke HA
    IDrugs; 2007 Jan; 10(1):37-41. PubMed ID: 17187313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic applications of antiflammin peptides in experimental ocular inflammation.
    Chan CC; Tuaillon N; Li Q; Shen DF
    Ann N Y Acad Sci; 2000; 923():141-6. PubMed ID: 11193752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical Development of EBI-005: An IL-1 Receptor-1 Inhibitor for the Topical Ocular Treatment of Ocular Surface Inflammatory Diseases.
    Kovalchin J; King B; Masci A; Hopkins E; Fry J; Hou J; Li C; Tenneson K; Weber S; Wolfe G; Collins K; Furfine ES
    Eye Contact Lens; 2018 May; 44(3):170-181. PubMed ID: 28727604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ectoine in the Treatment of Irritations and Inflammations of the Eye Surface.
    Bilstein A; Heinrich A; Rybachuk A; Mösges R
    Biomed Res Int; 2021; 2021():8885032. PubMed ID: 33628826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allergy and Dry Eye Disease.
    Leonardi A; Modugno RL; Salami E
    Ocul Immunol Inflamm; 2021 Aug; 29(6):1168-1176. PubMed ID: 33544639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II drugs under investigation for allergic conjunctivitis.
    Baiula M; Spampinato S
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1671-86. PubMed ID: 25062902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The management of allergic eye diseases in primary eye care.
    Chigbu DI
    Cont Lens Anterior Eye; 2009 Dec; 32(6):260-72. PubMed ID: 19879797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term progression, prognosis, and treatment of patients with recurrent ocular manifestations of Reiter's syndrome.
    Kiss S; Letko E; Qamruddin S; Baltatzis S; Foster CS
    Ophthalmology; 2003 Sep; 110(9):1764-9. PubMed ID: 13129875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moving forward in uveitis therapy: preclinical to phase II clinical trial drug development.
    Salazar-Méndez R; Yilmaz T; Cordero-Coma M
    Expert Opin Investig Drugs; 2016; 25(2):195-214. PubMed ID: 26640977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ocular allergy as a risk factor for dry eye in adults and children.
    Villani E; Rabbiolo G; Nucci P
    Curr Opin Allergy Clin Immunol; 2018 Oct; 18(5):398-403. PubMed ID: 30015640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ocular allergic disorders and dry eye disease: associations, diagnostic dilemmas, and management.
    Berdy GJ; Hedqvist B
    Acta Ophthalmol Scand Suppl; 2000; (230):32-7. PubMed ID: 11057347
    [No Abstract]   [Full Text] [Related]  

  • 36. Recent overview of ocular patents.
    Gaudana RJ; Gokulgandhi MR; Boddu SH; Mitra AK
    Recent Pat Drug Deliv Formul; 2012 Aug; 6(2):95-106. PubMed ID: 22493994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Emphasizing the prevention and anti-inflammation research of dry eye disease].
    Zhang MC; Bian F
    Zhonghua Yan Ke Za Zhi; 2013 Jan; 49(1):6-7. PubMed ID: 23601457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical review: topical ophthalmic use of cyclosporin A.
    Utine CA; Stern M; Akpek EK
    Ocul Immunol Inflamm; 2010 Oct; 18(5):352-61. PubMed ID: 20735287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Ocular allergies].
    Messmer EM
    Ophthalmologe; 2005 May; 102(5):527-43; quiz 544. PubMed ID: 15806370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel drug delivery systems for the management of dry eye.
    Nagai N; Otake H
    Adv Drug Deliv Rev; 2022 Dec; 191():114582. PubMed ID: 36283491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.